China Medical System Holdings said its subsidiary Dermavon Holdings received acceptance from China’s NMPA for a new drug application seeking an additional indication for ruxolitinib phosphate cream to treat mild to moderate atopic dermatitis, and the filing was granted priority review by the CDE. Dermavon holds an exclusive license from Incyte to develop, register and commercialize the product in Mainland China, Hong Kong, Macau, Taiwan and 11 Southeast Asian countries, with a non-exclusive manufacturing license in the same territory.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260224-12028653), on February 24, 2026, and is solely responsible for the information contained therein.